Obesity and its related complications have become an important public health concern. Traditional lifestyle modification and earlier pharmacotherapies provide only limited weight reduction. There is an urgent need for more effective treatments. Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist (GIP/GLP-1 RA). Its distinctive pharmacological mechanisms and outstanding effects on weight loss have attracted wide attention. Although initial studies on tirzepatide mainly focused on type 2 diabetes mellitus (T2DM), evidence in adults with obesity without T2DM has expanded rapidly. Available human evidence supports reduced appetite and energy intake as major contributors to weight reduction, whereas mechanisms involving central neural circuits, adipose-tissue remodeling, and biased receptor signaling remain largely preclinical or translational. In available clinical trials, tirzepatide has been shown to produce substantial weight reduction and appears to be among the most effective obesity management medications (OMMs), although most comparisons beyond SURMOUNT-5 remain indirect. Its safety profile is characterized mainly by mild-to-moderate gastrointestinal symptoms during dose escalation, while long-term and rare safety outcomes require continued evaluation. In this narrative review, we summarize the mechanisms, clinical efficacy, safety, comparative positioning, and evidence gaps relevant to long-term real-world evaluation and next-generation incretin-based therapies.

Background:Lipoprotein(a)-targeted therapies are emerging approaches for lowering lipoprotein(a) [lp(a)]. Objective:We conducted a systematic review and network meta-analysis to evaluate the efficacy and safety of lipoprotein(a)-targeted therapies in patients. Methods:We searched PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to May 6, 2025, for randomized controlled trials (RCTs) with intervention duration of at least 12 weeks. The primary outcomes were percentage and absolute changes in Lp(a). Secondary outcomes included changes in low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB), and safety outcomes including adverse events (AEs), serious adverse events (SAEs), and injection-site reactions. A frequentist framework network meta- analysis was performed. Results:Nine studies involving 1,432 participants were included. All six Lp(a)-targeted therapies significantly reduced Lp(a) levels. Compared with placebo, Olpasiran was the most effective therapy for both percentage [mean difference: -92.06, 95% (-109.80; -74.32), P-score: 0.94] and absolute reductions [-250.70 (-262.04; -239.36), P-score: 0.99], followed by Zerlasiran [-78.33 (-92.18; -64.48), P-score: 0.70], [-205.63 (-217.24; -194.03), P-score: 0.76]. In between-drug comparisons, Olpasiran was superior to Pelacarsen. Both Olpasiran and Zerlasiran were associated with improved LDL-C and apoB concentrations. Zerlasiran, Lepodisiran, and Pelacarsen were found to increase the risk of injection-site reactions. Conclusions:Lp(a)-targeted therapies achieved substantial reductions in Lp(a). Olpasiran was the most effective agent in lowering Lp(a) levels. These therapies also improved LDL-C and apoB. The majority of Lp(a)-targeted therapies demonstrate generally favorable safety profiles; However, injection-site reactions, particularly with Zerlasiran, warrant careful consideration. Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO/view/CRD420251069288, PROSPERO CRD420251069288.

ObjectiveTo explore the current research status and trends of potassium-competitive acid blockers (P-CABs) in the treatment of acid related diseases (ARDs) using bibliometric analysis.Materials and methodsWe collected publications related to P-CAB in the treatment of acid-related diseases in the Web of Science (WOS) Core Collection from the establishment of the database to 30 June 2024. We evaluated the publication volume and citation status over the years using the WOS platform, and visualized the authors, countries, institutions, keywords, and citations of the publications using CiteSpace and VOSviewer.ResultsThis study included a total of 455 articles. The number of publications and citations related to research has been increasing year by year. The results show that the scholars with the highest number of publications mainly come from South Korea and Japan. Scholars such as Geun Seog Song, Bongtae Kim, and Nobuhiro Inatomi produced many works in related fields. The most popular drug in this field was vonoprazan, and research on this drug mainly focused on the effectiveness and safety evaluation of ARDs such as Helicobacter pylori infection, gastroesophageal reflux disease, peptic ulcers, etc. Researchers were concerned about the evaluation of treatment regimens and efficacy comparison between P-CABs and traditional proton pump inhibitors (PPIs) in the treatment of ARDs. At the same time, researchers are also closely monitoring the potential adverse reactions and long-term adverse outcomes of clinical application of P-CABs for ARDs.ConclusionThe clinical application of P-CABs, represented by vonoprazan, in ARDs is receiving widespread attention from researchers. The exploration of the application of this type of drug in ARDs is constantly expanding, and it is a research field with great clinical value and research potential.

In order to evaluate the effectiveness and safety of high-dose dual therapy with vonoprazan for eradicating Helicobacter pylori, we searched seven electronic databases from the establishment of the database to March 2025, collecting randomized controlled clinical trials (RCTs) comparing high-dose dual therapy with vonoprazan to high-dose dual therapy with PPI and quadruple therapy with bismuth, including 13 RCTs with 4023 patients. The primary outcome is the eradication rate determined based on intention to treat analysis and protocol analysis, while secondary outcomes include incidence of adverse events and compliance. According to ITT analysis and PP treatment analysis, the eradication rates of VA therapy were 88.81 % and 93.56 %, respectively. The incidence of adverse reactions was significantly lower (14.56 % vs 26.00 %, RR=0.57, 95 % CI: 0.48-0.67, p < 0.0001), and compliance was better (96.29 % vs 93.56 %, RR=1.03, 95 % CI: 1.01-1.05, p = 0.003), making it a reliable alternative therapy.

Purpose Patients with advanced non-small cell lung cancer (NSCLC) mostly receive essential routine care and support from informal caregivers, who usually experience poorer health-related quality of life (HRQoL). The study aimed to evaluate the HRQoL and its predictors among informal caregivers of patients with advanced NSCLC in China. Methods We interviewed the adult caregiver population of patients with advanced NSCLC (stage IIIB~IV) in nine tertiary hospitals from multiple provinces in China between November 2020 and June 2021. The EQ-5D-5L instrument measured the HRQoL of caregivers, as analyzed by employing descriptive analysis, univariate analysis, Tobit regression, and multivariate logistic regression, and investigated the important influencing factors further. Results A valid sample of 553 caregivers was analyzed. The mean EQ-5D-5L utility score of caregivers was 0.92 (SD = 0.14). Caregivers reported the greatest problems in mental health, with 45.39% reporting slight, moderate, severe, or extreme anxiety/depression. The potential influencing factors of HRQoL in caregivers included patients' age and cancer histology, relationship with the patients, and daily caregiving hours. Compared to other caregivers, patients' spouses had the lowest HRQoL. In addition, over six hours of caregiving per day was associated with lower HRQoL in caregivers of patients with advanced NSCLC. Conclusions The HRQoL of caregivers for patients with advanced NSCLC was investigated for the first time in China. The informal caregivers experience decreased HRQoL, with anxiety /depression problems being reported the most. The findings of this study would provide extensive information on the HRQoL of advanced NSCLC patients' caregivers for future health-promoting self-care.

Abstract There is little information on whether generic meropenem can be as safe and effective as brand-name meropenem. This retrospective study aimed to compare the efficacy and safety of generic vs brand-name meropenem for infection treatment. Patients (aged ≥18 years) prescribed generic or brand-name meropenem between January 1, 2020, and December 31, 2021, were identified from the hospital information system database of Sichuan Provincial People's Hospital and Sichuan Academy of Medical Sciences. The efficacy outcomes included clinical efficacy, changes in laboratory testing indicators related to infection, and bacterial clearance rate. Safety outcomes included incidence of adverse reactions, abnormal liver and kidney function indicators, and abnormal blood system indicators. A total of 2288 patients (1414 [61.8%] males and 874 [38.2%] females, mean [IQR] age 66 [52-77] years) were eligible for analysis, of whom 1234 were prescribed generic meropenem. Both the generic and the brand-name groups included 600 patients (729 [60.8%] female, mean [IQR] age, 63 [51-76] years) after propensity score matching. The generic meropenem was comparable to the brand-name drug about efficacy (447 [74.5%] vs 462 [77.0%]; P = 0.360). The generic meropenem was associated with lower rates of bacterial clearance (83 [13.8%] vs 120 [20.0%]; P = <0.001). The brand-name may have a better elimination effect on Escherichia coli compared with its generic counterpart (6 [20.0%] vs 25 [55.6%]; P = 0.002). The risks of adverse reactions were not significantly different between the two groups (20 [3.3%] vs 25 [4.2%]; P = 0.447). In conclusion, the generic meropenem was as effective and safe as brand-name meropenem in adult hospitalized patients diagnosed with serious bacterial infections.

Patients with type 2 diabetes mellitus (T2DM) are at higher risk for urinary tract infections (UTIs), which greatly impacts their quality of life. Developing a risk prediction model to identify high-risk patients for UTIs in those with T2DM and assisting clinical decision-making can help reduce the incidence of UTIs in T2DM patients. To construct the predictive model, potential relevant variables were first selected from the reference literature, and then data was extracted from the Hospital Information System (HIS) of the Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital for analysis. The data set was split into a training set and a test set in an 8:2 ratio. To handle the data and establish risk warning models, four imputation methods, four balancing methods, three feature screening methods, and eighteen machine learning algorithms were employed. A 10-fold cross-validation technique was applied to internally validate the training set, while the bootstrap method was used for external validation in the test set. The area under the receiver operating characteristic curve (AUC) and decision curve analysis (DCA) were used to evaluate the performance of the models. The contributions of features were interpreted using the SHapley Additive ExPlanation (SHAP) approach. And a web-based prediction platform for UTIs in T2DM was constructed by Flask framework. Finally, 106 variables were identified for analysis from a total of 119 literature sources, and 1340 patients were included in the study. After comprehensive data preprocessing, a total of 48 datasets were generated, and 864 risk warning models were constructed based on various balancing methods, feature selection techniques, and a range of machine learning algorithms. The receiver operating characteristic (ROC) curves were used to assess the performances of these models, and the best model achieved an impressive AUC of 0.9789 upon external validation. Notably, the most critical factors contributing to UTIs in T2DM patients were found to be UTIs-related inflammatory markers, medication use, mainly SGLT2 inhibitors, severity of comorbidities, blood routine indicators, as well as other factors such as length of hospital stay and estimated glomerular filtration rate (eGFR). Furthermore, the SHAP method was utilized to interpret the contribution of each feature to the model. And based on the optimal predictive model a user-friendly prediction platform for UTIs in T2DM was built to assist clinicians in making clinical decisions. The machine learning model-based prediction system developed in this study exhibited favorable predictive ability and promising clinical utility. The web-based prediction platform, combined with the professional judgment of clinicians, can assist to make better clinical decisions.

Fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) are key indicators reflecting blood glucose control in type 2 diabetes mellitus (T2DM) patients. The purpose of this study is to establish a predictive model for blood glucose changes in T2DM patients after 3 months of treatment, achieving personalized treatment.A retrospective study was conducted on type 2 diabetes mellitus real-world medical data from 4 cities in Sichuan Province, China from January 2015 to December 2020. After data preprocessing, data inputting, data sampling, and feature screening, 16 kinds of machine learning methods were used to construct prediction models, and 5 prediction models with the best prediction performance were screened respectively. A total of 100,000 cases were included to establish the FBG model, and 2,169 cases were established to establish the HbA1c model. The best prediction model both of FBG and HbA1c finally obtained are realized by ensemble learning and modified random forest inputting, the AUC values are 0.819 and 0.970, respectively. The most important indicators of the FBG and HbA1c prediction model were FBG and HbA1c. Medication compliance, follow-up outcome, dietary habits, BMI, and waist circumference also had a greater impact on FBG levels. The prediction accuracy of the models of the two blood glucose control indicators is high and has certain clinical applicability.HbA1c and FBG are mutually important predictors, and there is a close relationship between them.

BackgroundSince 2009, a series of ambitious health system reforms have been launched in China, including the zero mark-up drug policy (ZMDP); the policy was intended to reduce substantial medicine expenses for patients by abolishing the 15% mark-up on drugs. This study aims to evaluate the impacts of ZMDP on medical expenditures from the perspective of disease burden disparities in western China. MethodTwo typical diseases including Type 2 diabetes mellitus (T2DM) in internal medicine and cholecystolithiasis (CS) in surgery were selected from medical records in a large tertiary level-A hospital in SC Province. The monthly average medical expenses of patients from May 2015 to August 2018 were extracted to construct an interrupted time series (ITS) model to evaluate the impact of policy implementation on the economic burden. ResultsA total of 5,764 cases were enrolled in our study. The medicine expenses for T2DM patients maintained a negative trend both before and after the intervention of ZMDP. It had declined by 74.3 CNY (P < 0.001) per month on average in the pre-policy period and subsequently dropped to 704.4 CNY (P = 0.028) immediately after the policy. The level change of hospitalization expenses was insignificant (P = 0.197), with a reduction of 677.7 CNY after the policy, while the post-policy long-term trend was significantly increased by 97.7 CNY (P = 0.035) per month contrasted with the pre-policy period. In addition, the anesthesia expenses of T2DM patients had a significant increase in the level under the impact of the policy. In comparison, the medicine expenses of CS patients significantly decreased by 1,014.2 CNY (P < 0.001) after the policy, while the total hospitalization expenses had no significant change in level and slope under the influence of ZMDP. Furthermore, the expenses of surgery and anesthesia for CS patients significantly increased by 320.9 CNY and 331.4 CNY immediately after the policy intervention. ConclusionOur study indicated that the ZMDP has been an effective intervention to reduce the excessive medicine expenses for both researched medical and surgical diseases, but failed to show any long-term advantage. Moreover, the policy has no significant impact on relieving the overall hospitalization burden for either condition.

ABSTRACT Objectives Taxane‐related neurotoxicity is a frequent clinical problem but lacks postmarketing data regarding neurological disorders. This study aimed to evaluate the potential association between neurological adverse events and several taxanederived drugs via the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods Disproportionality analysis was applied to data mining of the suspected cases of neurological disorders after using different taxanes based on the FAERS data from January 2017 and December 2021. We also investigated the times to onset, fatality, and hospitalization proportions of taxanerelated neurotoxicity. Results In total, 3,940 cases were screened out, which were more prevalent in elderly patients and females. Peripheral neuropathy was a common adverse event among all taxanes with relatively strong association. Generally, the median time to neurological adverse effect onset was 27 days (interquartile range, 11.0 ~ 78.0 days) following taxane regimens, and the majority of cases were detected within the first 30 days. Among cases of neurological adverse events treated with taxane, the fatality and hospitalization proportions were 6.13% and 28.63%, respectively. Conclusion By analyzing the FAERS data, we provided a detailed profile of neurotoxicity and different taxanes in detail in terms of clinical characteristics, time to onset, and patient outcomes.

目的 分析非酒精性脂肪肝病(NAFLD)治疗研究现状、热点及发展趋势,为后续研究提供参考.方法 检索Web of Science数据库,收集建库起至2022年12月31日治疗NAFLD的相关文献,利用CiteSpace 6.1.R6构建可视化图谱,对作者、国家及机构进行合作网络分析,同时进行关键词共现、聚类和突现分析,分析其研究现状和热点.结果 共纳入文献3 882篇,发文量呈逐年增长的趋势.发文量排名前3位的国家为中国、美国和日本.发文量最多的作者是美国的Sanyal(37篇),发文量最多的机构是加州大学圣地亚哥分校(75篇).国外联系紧密的研究团队以大型随机对照试验(RCT)为主,对包括药物、生活方式等多种干预措施治疗NAFLD的有效性和安全性进行了评估;而国内研究以有效药用成分治疗NAFLD的基础研究为主,且以中医药为特色,相关的高质量大型RCT较少.关键词分析结果显示,各国研究以调控肝脏氧化应激和炎症、改善全身糖脂代谢平衡为主,除降糖药物外,作用于多种综合调控体内代谢稳态靶点的药物进入临床试验阶段,具有巨大的治疗潜力.结论 NAFLD治疗研究热度持续增长,并以调控全身代谢稳态靶点和相关药物为研究导向.作为研究主力,我国应加强与国际的交流,把握基础研究的趋势,重视临床研究的开展,不断挖掘传统中药的治疗潜力.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is considered a “multisystem” disease that simultaneously suffers from metabolic diseases and hepatic steatosis. Some may develop into liver fibrosis, cirrhosis, and even hepatocellular carcinoma. Given the close connection between metabolic diseases and fatty liver, it is urgent to identify drugs that can control metabolic diseases and fatty liver as a whole and delay disease progression. Ferroptosis, characterized by iron overload and lipid peroxidation resulting from abnormal iron metabolism, is a programmed cell death mechanism. It is an important pathogenic mechanism in metabolic diseases or fatty liver, and may become a key direction for improving MASLD. In this article, we have summarized the physiological and pathological mechanisms of iron metabolism and ferroptosis, as well as the connections established between metabolic diseases and fatty liver through ferroptosis. We have also summarized MASLD therapeutic drugs and potential active substances targeting ferroptosis, in order to provide readers with new insights. At the same time, in future clinical trials involving subjects with MASLD (especially with the intervention of the therapeutic drugs), the detection of serum iron metabolism levels and ferroptosis markers in patients should be increased to further explore the efficacy of potential drugs on ferroptosis.

丁苯酞(NBP)为多靶点抗脑缺血药物,具有保护线粒体、抗氧化、抑制神经炎症等作用.NBP主要用于治疗轻、中度急性缺血性脑卒中,可改善缺血性脑卒中患者的神经功能、认知功能和生活能力,疗效确切且安全性好.近年来大量研究显示,NBP的作用靶点与帕金森病(PD)的主要病理途径吻合,能显著改善患者临床症状和生命体征,治疗PD具有巨大潜力.该文对NBP治疗PD的临床前研究及临床试验研究进行总结,以期为治疗PD提供新思路.

慢性阻塞性肺疾病(COPD)是一种以气流受限和呼吸困难为特征的肺部疾病;2 型糖尿病(T2DM)是一种以血糖代谢异常为特征的疾病.COPD与T2DM之间存在一定联系,也常构成慢性共病,给患者造成巨大的风险.二甲双胍是目前用于T2DM的一线降糖药物,可通过改善胰岛素拮抗降低糖尿病患者血糖.近年来,随着研究的不断深入,二甲双胍针对COPD表现出抗炎、抗氧化应激、抗感染等作用,对COPD及伴有T2DM并发症的COPD患者具有潜在的临床效益,有望成为新的T2DM合并COPD慢性共病的治疗途径.该文对二甲双胍治疗T2DM合并COPD相关研究进行综述,以期为COPD合并T2DM的治疗提供参考.

Objective This study was conducted to estimate the direct non-medical cost of advanced non-small cell lung cancer (NSCLC) patients and explore whether its associated factors vary by health status. Methods Data were obtained from 13 centers in five provinces for patients with advanced NSCLC in China. The direct non-medical cost of patients since the patients were diagnosed with NSCLC included the cost of transportation, accommodation, meal, hired caregiving, and nutrition. We measured patients' health status by EQ-5D-5L instrument and divided them into good (≥0.75) and poor (<0.75) groups based on the utility score. A generalized linear model (GLM) was used to assess independent associations between statistically significant factors and non-medical financial burden in health status subgroups. Results Data from 607 patients were analyzed. The direct non-medical cost associated with advanced NSCLC since diagnosis was $2,951 per case ($4,060 in the poor health group and $2,505 in the other), with nutrition costing the most. GLM results showed that residence(Urban area vs. Rural area: −1.038, [−2.056, −0.02]), caregivers' occupation type (Farmer vs. Employee: −1.303, [−2.514, −0.093]), hospitalization frequency (0.077, [0.033, 0.12]), average length of hospital stay (0.101, [0.032, 0.17]), and pathological type (Squamous carcinoma vs. Non-squamous carcinoma: −0.852, [−1.607, −0.097]) were independent factors influencing direct non-medical cost in the poor health group. Among participants with good health status, residence (Urban area vs. Rural area: −0.621, [−1.005, −0.236]), marital status (Others vs. Married: 0.762, [0.035, 1.488]), patients' employment status, current caregiving time per day (more than 9 hours per day vs. less than 3 hours per day: 0.471, [0.134, 0.807]), duration of disease (0.015, [0.007, 0.024]), and hospitalization frequency (0.091, [0.068, 0.113]) were statistically associated factors. Conclusion The direct non-medical economic burden of advanced NSCLC patients in China is considerable and differs by health status. Strengthening accessibility for more effective therapies and early nutritional intervention to improve prognosis, and further promoting accessible care forms within relevant healthcare insurance coverage may be potentially feasible approaches to alleviate the direct non-medical economic burden for patients and their families.

运动性支气管收缩(EIB)指运动诱发的急性气道狭窄.大量研究表明,运动员EIB发病率比普通人群更高,且与从事运动的种类相关.从事夏季运动如铁人三项、自行车项目的运动员,以及从事冬季运动如越野滑雪、冰球、北欧两项等耐力性、力量速度性项目的运动员,哮喘和肺部功能异常情况发生率较高.对于运动员而言,积极采取措施做好气道防护,最大限度地减少运动对气道功能可能产生的有害影响是实现最佳成绩的必要条件.EIB可以通过药物手段和非药物手段进行预防和治疗,以降低运动员的发病风险.笔者在该文对运动员发生EIB的原因展开分析并提出相关防治策略及建议,以期提高对EIB认识程度及管理水平,为广泛开展冬季冰上运动提供健康保障.

Purpose This study was conducted to estimate the indirect cost of locally advanced and metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR and ALK alterations in China and explore the predictors from both patient and caregiver perspectives. Methods Data were obtained from a nationwide cross-sectional study for the patients with advanced NSCLC (stage IIIB–IV) and their caregivers. Indirect medical cost was estimated as health productivity loss based on self-reported income and loss of work time. The generalized linear model was used to assess the independent associations between statistically significant variables and indirect economic burden. Results 611 pairs of patients and patient caregivers from 13 medical centers in five provinces in China participated in this investigation. The indirect medical cost associated with advanced NSCLC since the patient diagnosed was $1413 per capita in China. General linear regression results showed that the indirect medical cost was significantly influenced by duration of disease since diagnosis, treatment options, caregivers’ occupation and age ( P < 0.05). Conclusion The indirect economic burden linked to advanced NSCLC in China is considerable on patients, and their caregivers. To minimize the severe challenges of indirect economic burden related to advanced NSCLC, expanding the coverage of the medical insurance and assistance system to reimburse part of the indirect costs related to cancer, as well as strengthening the accessibility for more effective therapies to improve the prognosis of advanced NSCLC, and further promote the patients and their caregivers to return to work or normal life may be the potentially feasible approaches.

目的 对免疫相关性妊娠多学科诊疗(MDT)门诊的全程化药学服务模式、流程及成果进行介绍,为提升药物治疗有效性、安全性和患者依从性提供参考.方法 以合并风湿免疫的基础疾病、或者因为免疫异常等因素而存在复发性流产的患者为服务对象,介绍本院免疫相关性妊娠MDT门诊的团队构建、工作模式和临床药师职责.统计分析215例免疫相关性妊娠患者的一般情况、疾病情况、合并用药情况、药学服务内容、患者孕期并发症发生情况及母儿结局.结果 药师为215例MDT门诊就诊患者提供了全程化药学服务,包括用药史回顾、医嘱审核、药物重整、用药教育和生活方式指导,回答家属咨询,解答患者疑问,并就用药方案及治疗方案调整提出意见建议,开展患者随访、药物不良反应监测等,患者满意度达100％.在有效随访且有妊娠结局的53例就诊患者中,活产47例,活产率87.04％;2例自然流产,自然流产率3.78％;2例治疗性流产,治疗性流产率3.78％;2例胎死宫内,胎死宫内发生率3.78％;1例出生缺陷,产检发现胎儿脑积水,母亲选择性终止妊娠(羊膜腔穿刺引产),出生缺陷率为1.86％,相较于我国总人群的出生缺陷发生率(5.6％)明显偏低.18例患者出现并发症;其中妊娠糖尿病最多(6例),发生率为11.32％;妊娠高血压(3例)发生率5.66％.结论 临床药师通过开设MDT门诊,参与特殊患者全程化药物治疗管理,可提高合理用药水平、患者依从性、药物治疗安全性及治疗效果.

目的 分析临床药师参与肾上腺皮质功能减退症患者主动脉假性动脉瘤手术期间的治疗药物管理,为特殊人群围手术期的用药管理提供经验.方法 临床药师参与制定肾上腺皮质功能减退症患者假性动脉瘤围手术期补充糖皮质激素的剂量、手术中糖皮质激素的应用以及手术后糖皮质激素的治疗方案.结果 在临床药师和医护的共同努力下,成功为该患者完成了假性动脉瘤手术.结论 临床药师参与特殊人群的围手术期药物管理可提高患者在围手术期间的安全性.